{"name":"Enanta Pharmaceuticals, Inc","slug":"enanta-pharmaceuticals-inc","ticker":"","exchange":"","domain":"enanta.com","description":"","hq":"Watertown","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":102814000,"revenueGrowth":35.4,"grossMargin":0,"rdSpend":106740000,"netIncome":-81889000,"cash":280732000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"DEB025","genericName":"DEB025","slug":"deb025","indication":"Other","status":"phase_1"},{"name":"EDP-235","genericName":"EDP-235","slug":"edp-235","indication":"Other","status":"phase_2"},{"name":"EDP-323 Dose Regimen 2","genericName":"EDP-323 Dose Regimen 2","slug":"edp-323-dose-regimen-2","indication":"Other","status":"phase_2"},{"name":"EDP-297","genericName":"EDP-297","slug":"edp-297","indication":"Other","status":"phase_1"},{"name":"EDP-323","genericName":"EDP-323","slug":"edp-323","indication":"Other","status":"phase_1"},{"name":"EDP-323 Dose Regimen 1","genericName":"EDP-323 Dose Regimen 1","slug":"edp-323-dose-regimen-1","indication":"Other","status":"phase_2"},{"name":"EDP-494","genericName":"EDP-494","slug":"edp-494","indication":"Other","status":"phase_1"},{"name":"EDP239","genericName":"EDP239","slug":"edp239","indication":"Other","status":"phase_1"},{"name":"intraconazole","genericName":"intraconazole","slug":"intraconazole","indication":"Other","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Carbamazepin","genericName":"Carbamazepin","slug":"carbamazepin","indication":"Bipolar affective disorder, current episode manic","status":"marketed"}]}],"pipeline":[{"name":"DEB025","genericName":"DEB025","slug":"deb025","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Carbamazepin","genericName":"Carbamazepin","slug":"carbamazepin","phase":"marketed","mechanism":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","indications":["Bipolar affective disorder, current episode manic","Bipolar disorder in remission","Epilepsy","Epilepsy characterized by intractable complex partial seizures","Glossopharyngeal neuralgia"],"catalyst":""},{"name":"EDP-235","genericName":"EDP-235","slug":"edp-235","phase":"phase_2","mechanism":"EDP-235 is a core protein allosteric modulator (CpAM) that disrupts HBV capsid assembly and viral replication.","indications":[],"catalyst":""},{"name":"EDP-323 Dose Regimen 2","genericName":"EDP-323 Dose Regimen 2","slug":"edp-323-dose-regimen-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EDP-297","genericName":"EDP-297","slug":"edp-297","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EDP-323","genericName":"EDP-323","slug":"edp-323","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EDP-323 Dose Regimen 1","genericName":"EDP-323 Dose Regimen 1","slug":"edp-323-dose-regimen-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EDP-494","genericName":"EDP-494","slug":"edp-494","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EDP239","genericName":"EDP239","slug":"edp239","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"intraconazole","genericName":"intraconazole","slug":"intraconazole","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPY3duMlJnN2ZiWFYwN01IVEgxNERJbkM3dkx2Y2ZTdXRsRUxHd3J0c1VhX19vUDNmTW4yd0dRb0tCX1FySkgyMDQ1M0JDS3Q3UTRhUTdZN3N4eVBWYWpoemYxdTlEYkgyVlFSRG9mMFI0U1NzQWxwQkR0VWpzU3h4X1lYZDdTMlY5TEVtZ1RuU0VlZjNQMW1aTWRBZG4tNGxBTGhWZ29kby1XdndjY1RweFo0dHZkY2w0MGxSXzRrbGZhSWdqaUVVYUxHTmkzeGt5elhUaC1LYVlLdTdWcm1SVng4VjJOdF9s?oc=5","date":"2026-01-08","type":"pipeline","source":"businesswire.com","summary":"Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook - businesswire.com","headline":"Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPRnY2cDM1YkdLc1ZMek1Ec3lOYmxsTG8za1ZqbG13TkNmcVVlT19hZlFHR2xMWnFYQUdORnFVS3VtbVhlZTBTRE1uS2lXUk9ONVBDa0Q5ZVkzX1VNaGIwZk9VNTZrckhFUzIyZW84WVZ2dHJCZjNQWk52UEFBa1lTaGNNX29VNkxEVWpfLUZIWVhUdWF3ZjdxVkYxS2VlYTB4LUtLaHpRc1RyU1JabDh0RG5LNFdnSkQxVFRN?oc=5","date":"2025-11-17","type":"earnings","source":"Investing.com","summary":"Enanta Pharma posts narrower-than-feared Q4 loss as expenses decline - Investing.com","headline":"Enanta Pharma posts narrower-than-feared Q4 loss as expenses decline","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOZFB2Y3lnOFY0dDNsYlBINzNFRmNFY2llWTRaNDhoQmw2b09rT25POXp2SFEtQ2piMExSVU53UUFWYjFxUE9uNm4zS1U0RzBXd01JYWNTUW1IYzU5dnF2cWlSTlZUMHBFVUVoUGdycW5vZjhOVVh5N2ZQaFQwdXRDRWRqQlNEZEtqeXdnM1NPb05sODY2N1Nuc1hlczQ5c0FnRTVRTmFkallUYzRnbGZoaTFUUEVUY1h3dEFzd1M1dWhTQkphTVVqck5R?oc=5","date":"2025-09-30","type":"pipeline","source":"businesswire.com","summary":"Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock - businesswire.com","headline":"Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOS3E2S1ozbW84enJWbmRVY1JDZzhZdWctZXRmTFdRQ1ZnTXcxeVVGUUJDWlo4NlpFblNTR0FtTUJCRUxreGxSaVN2MnAzNkRDejdRUDR6VWh2WXVLQWo3TDFNLVFmMG9uNklHX2FjLUc3cWVmS3dFYzhqWDBJZVZ1VnlPMWlma29iM0IwVjVaeTk4OFNOM1dkc0kxU2lmV2p4MnRwMi0yT3N1TFNfd2RuZ08tOERZeGNOR2x0T1NKTFEyWXlmRXc0a20wQUs5RHhzVkRxM1NxbTZ4eDFIT3BzbzV0YzM4aGdNcGc?oc=5","date":"2025-09-29","type":"pipeline","source":"Stocktwits","summary":"Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update - Stocktwits","headline":"Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9fbnFsWVNCUUU1Z0hlTzV5azVBR0ZXZEhfVFJqdnNuQ0JrLUF3a1RZSkpsSlM4dXI3Tm9FOU1JcS1xTGhqVF9iLS1EekZUS050dzlRNnNJSjNXc3hDcVBfOVViLXhQSXZpMUxqdDc2WkJTdkxRX1VjXzM3M3o?oc=5","date":"2025-09-29","type":"trial","source":"pharmaphorum","summary":"Enanta weakens on RSV treatment trial readout - pharmaphorum","headline":"Enanta weakens on RSV treatment trial readout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNTl8tUEI1Y200dFlTeVpubHAwZTFQNFlicC1CSzZRcmRBV2t4MkRhWmFxSm1fa2U2SDFlcmczZFFzc1lrTVhKcnRCbHc2OElROUFvcGc4MWVXZWZEeUtXeWw0RTlsNlRRRXhyV0h4clo4ZDcyYUp2ejViM0Zrc2RSWEJScUx3WjN2dGxrdGYwR1Z5SVUxQ3hpQVd1OWQtOG84YUdwVmMxeHpiRjFZZk9tRmxRZmE?oc=5","date":"2025-09-29","type":"trial","source":"Seeking Alpha","summary":"Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change - Seeking Alpha","headline":"Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPVlc1ZkwxbXdsa1VMMm1rYWJsTTUxbUdIZ2tQcnpKMWhRVHpGVzE5elpaclNFYU1iN1NYVjV0eXJHYVduaEdFTkhJVjdqQnNGd0J4MWZlSUUxekFuZXN2ZWZqT3J6VmhKbVlhSERZaW1ZVUJYY0hES1Y3Z015Vl9IWFZ1cnFWQnE0UWJzb3lkMDFHeHhzMkJVZzQwYndPTFZY?oc=5","date":"2025-08-20","type":"pipeline","source":"Pharmaceutical Technology","summary":"Pfizer battles another Paxlovid lawsuit from Enanta - Pharmaceutical Technology","headline":"Pfizer battles another Paxlovid lawsuit from Enanta","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPMGZkT1NDQ1FaUlM4TXdhaE13UlA4STZBRUFiQ29sQkg5NmpYRkpjWmhKNEdOel9fdFdhODZXcEZYNWIwZ3pSaEE2aWluOTBlV25mYmVjdU5JLTNsZTJLeEI0QzB2ZWpTNXlrZzJMYnZCS01hVjRadGNQN0hCTHh2N1lqRGg1SmVzZTMzcWZwWldWU2loVDI2UkhtSXdwUHI2YmxnQzdISlZWZWRfZXBBd3hIZ2JKOEFuRnk4RUlPcW9tVm5YLXBDRXFhUGY5ekQtUXEwWXRkUkI4ckZ4YzJuYnFuTE1BVXpD?oc=5","date":"2025-08-11","type":"earnings","source":"businesswire.com","summary":"Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 - businesswire.com","headline":"Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1TTzlKWUwtMFVJVEpaUGJ3YmdLSkNDNHZ6ZEh2S042QVVpVnQ2ZDhKOFFoakdDYkpWT2JtWFhKaEltV1ctc0ZLc3dwWE1oRE5uSmtj?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"ENTA Stock Price, News & Analysis | Enanta Pharmaceuticals - Stock Titan","headline":"ENTA Stock Price, News & Analysis | Enanta Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOdmtsejhaVFNFSDFKbDFhZ1ZnMExKenNCVjRwSEsxNURDelV0S0Z0eTFBNTY4TzJKVEl0d25JNmROMFhDZk1xOTVyTGZIM21qeS1RWFZjLXZxal9xZkhkQ2FGT0FrR2hTdW9MRGtGajNfdEJiYzc0ZVhLTTBaaGJ2YldtTV9sZ1QyTjNiNndGNjE2NnNBWGZ5SzhWVTB2SWJXcUlrNmcydHI?oc=5","date":"2022-05-25","type":"pipeline","source":"The Business Journals","summary":"Biotech signs new lease in Alexandria’s Watertown ‘mega campus’ - The Business Journals","headline":"Biotech signs new lease in Alexandria’s Watertown ‘mega campus’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPUjBxaWNrREdlbUxsdVZoZFJhNGl5OUVkUEhCTTVQUUhTMHp0aXlSQjdzXzlxMnhWQlNFaG1GMzNhXzcyTXd5WGlIUlFNV19yaXBGajRYM2dkNFdpX25QZWNZSkxxbFVFQXRCS2ZtUm95Ny05S2YzWEdWbHAtZmJiMFBac2VCWHk3dlp0Xy1PNy12NFdGbmNFNnVR?oc=5","date":"2021-02-22","type":"pipeline","source":"Life Science Leader","summary":"A Behind The Scenes Look Into Enanta's CEO, Jay Luly - Life Science Leader","headline":"A Behind The Scenes Look Into Enanta's CEO, Jay Luly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPV2ZhV2hSSkZIYlpWQ1dKOXpDR3hYQlB1N1FwekJycFU4cWtQZjhraTN3ZmhBcUlablVYZnJXcHVKUnd0UTlJRlI5RVFOV2UtdWtrcmxiRm9HNVRyd3FEZllpYVdPY1dYTS1VaDhORFlOWWFfYWZGX0JrTHhKbXVzeGRFZnBaM0hqM0g3UGZGRkUza0NmaFRHckVIbHpCeWVUV3ZleVItTnFhMzV4MVR4cUk1NjdsZksyVnZ3MFNEQkM3c2p3ZnE5S1p2TERvcnRYbFo1TWdhbmhCVXQzWlU5Rkk1dXoyZ0VFd1lvV0N4Yw?oc=5","date":"2020-12-08","type":"pipeline","source":"BioSpace","summary":"Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development - BioSpace","headline":"Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strateg","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_1":6,"marketed":1,"phase_2":3},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":102814000,"revenuePeriod":"2017-09-30","revenueHistory":[{"value":102814000,"period":"2017-09-30"},{"value":75927000,"period":"2017-09-30"},{"value":7511000,"period":"2017-06-30"},{"value":8959000,"period":"2017-03-31"},{"value":10417000,"period":"2016-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":106740000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-81889000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":280732000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}